Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy.
about
Exploiting the Achilles' heel of membrane trafficking in trypanosomesDuplicated paralogous genes subject to positive selection in the genome of Trypanosoma bruceiGenotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawalA molecular mechanism for eflornithine resistance in African trypanosomesIsolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory miceAquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprolMelarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the CongoTransport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma bruceiPredictive computational models of substrate binding by a nucleoside transporter.Multiple genetic mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes.Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets.Evaluating 5-nitrofurans as trypanocidal agents.Genetic dissection of drug resistance in trypanosomesTrypanocidal furamidine analogues: influence of pyridine nitrogens on trypanocidal activity, transport kinetics, and resistance patterns.Nutrient transport and pathogenesis in selected parasitic protozoa.Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates.Nucleoside and nucleobase transporters in parasitic protozoa.A plethora of targets, a paucity of drugs: progress towards the development of novel chemotherapies for human African trypanosomiasis.Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomesThe molecular dynamics of Trypanosoma brucei UDP-galactose 4'-epimerase: a drug target for African sleeping sicknessPurine and pyrimidine transport in pathogenic protozoa: from biology to therapy.Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity.Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei.Whole genome sequencing shows sleeping sickness relapse is due to parasite regrowth and not reinfection.Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target.Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense.Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptakeTrypanocidal drugs: mechanisms, resistance and new targets.The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes.Drug resistance in human African trypanosomiasis.Functional analysis of drug resistance-associated mutations in the Trypanosoma brucei adenosine transporter 1 (TbAT1) and the proposal of a structural model for the protein.Susceptibility Testing of Medically Important Parasites.9-(2'-Deoxy-2'-Fluoro-β-d-Arabinofuranosyl) Adenine Is a Potent Antitrypanosomal Adenosine Analogue That Circumvents Transport-Related Drug Resistance.Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei.Acquired resistance to berenil in a cloned isolate of Trypanosoma evansi is associated with upregulation of a novel gene, TeDR40.
P2860
Q28066992-5437FA16-FBC3-401E-ACCF-997F4676F76BQ28472779-2F7C984F-14D1-470B-997B-6E7AB2D9D97AQ28476222-435ADFD6-8D48-42F2-99C6-142460093531Q28476349-8A14A200-CD44-49A3-9D1A-2DAE8E3605EDQ28477800-CD5168A9-A339-4E7D-BB31-7FD9292C1678Q28534313-F306B48E-BC33-4660-BECF-47E28A3A8EDBQ28543489-CAA1F19F-98D7-4A4B-A448-B7599CB54EEBQ28652499-A435BC7A-C8C0-4FC0-A96E-CE6E13DF7F80Q33553416-4B9B2668-15A4-49EC-B90D-E1018395E40DQ33659016-2CF1B69D-FECB-413F-8760-301C6DB276ECQ34145529-AFD01D7C-6DB9-4C30-A149-A0052ECA78EAQ34555495-B894569D-0729-4A56-AC2B-F0FE5B9BA564Q34647009-7BE7C91B-3A36-45F5-9179-C35434E36483Q34933034-8D9DA3A9-3685-4058-8986-B3776FD77ED9Q35080823-6F97425D-5832-43E5-97EB-2FA2C34A2B3FQ35645101-73BEC0C8-F19A-4F2F-97F7-E57983CB56CBQ35742322-F980A614-80E8-43BA-AFB9-AE391F2EED17Q35917161-A080DED4-702C-4337-BDCB-0D397CAE294FQ36079376-44EBFB33-FEEC-4756-8814-78AEC8521B27Q36103511-5C594386-4B87-4689-9A87-470DBFEC6744Q36205383-527A5983-39D6-4A0E-888B-25FD9A89B892Q36328558-6D1B7094-1B2D-473F-8BE6-B39C2C08A1C9Q36369970-00E6CCEA-3BAE-4D7C-AD22-D2E5AB26D793Q36485648-D5CFAA85-5140-4958-93B0-F76B4B66A0F4Q36969804-FEA7B7F5-D742-42D8-9599-D0DBE01E3CEFQ37139351-2EBB4A71-D9C5-46E2-8C70-82873A417A7CQ37317284-90817150-092D-43DD-B28C-B48C64DC17ACQ37390573-EE9A8A31-F229-4A80-ADED-0FFDEAF1AF8AQ37623081-9D99A134-0BBD-4484-AE8F-95E65773248FQ37734328-2B210798-9282-4EE6-8CB1-824BCF161F57Q37940573-9019AE8B-61F2-411A-8D3E-7D58BB19CF96Q38495661-3647620A-B73D-4B72-B2CA-E68C70EA785AQ39020376-D158832A-7DA7-441A-B369-A54F6C9A581DQ40266283-A4C4C63D-EEE2-4EEE-84EE-37BEB0301909Q43936767-F4B96928-4244-4DE8-AE18-7A9DBF785B94Q46779283-372D0DC5-8338-4658-BC26-C0E1D44381E5
P2860
Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Genetic variants of the TbAT1 ...... following melarsoprol therapy.
@en
type
label
Genetic variants of the TbAT1 ...... following melarsoprol therapy.
@en
prefLabel
Genetic variants of the TbAT1 ...... following melarsoprol therapy.
@en
P2093
P1476
Genetic variants of the TbAT1 ...... following melarsoprol therapy.
@en
P2093
Kaminsky R
Schneider V
P356
10.1016/S0166-6851(01)00332-2
P577
2001-09-01T00:00:00Z